` CLRB (Cellectar Biosciences Inc) vs S&P 500 Comparison - Alpha Spread

CLRB
vs
S&P 500

Over the past 12 months, CLRB has underperformed S&P 500, delivering a return of -87% compared to the S&P 500's 9% growth.

Stocks Performance
CLRB vs S&P 500

Loading
CLRB
S&P 500
Add Stock

Performance Gap
CLRB vs S&P 500

Loading
CLRB
S&P 500
Difference
www.alphaspread.com

Performance By Year
CLRB vs S&P 500

Loading
CLRB
S&P 500
Add Stock

Competitors Performance
Cellectar Biosciences Inc vs Peers

S&P 500
CLRB
ABBV
AMGN
GILD
VRTX
Add Stock

Cellectar Biosciences Inc
Glance View

Market Cap
16.8m USD
Industry
Biotechnology

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company is headquartered in Florham Park, New Jersey and currently employs 12 full-time employees. The company went IPO on 2005-05-20. The firm is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The Company, through Phospholipid Drug Conjugate (PDC) platform, is focused on to develop PDCs that are designed to target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs independently and through research and development collaborations. The Company’s product pipeline includes iopofosine, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets. The firm is also evaluating iopofosine in highly refractory multiple myeloma patients in its Phase II CLOVER-1 study and relapsed/refractory pediatric cancer patients with sarcomas or brain tumors in the Phase II CLOVER-2 study.

CLRB Intrinsic Value
0.3018 USD
Overvaluation 17%
Intrinsic Value
Price
Back to Top